|
|
Who We Are
The Cancer Letter
was founded in 1973 by journalist Jerry D. Boyd, two years after the U.S. Congress passed the National Cancer
Act of 1971. The Act increased support for research, training, and public education to reduce the burden of cancer. The Cancer Letter chronicled the development and growth of cancer research, new therapies, and the oncology profession. Boyd retired in 1990, turning over the company to his daughter Kirsten Boyd Goldberg, who served as editor and publisher for the next 20 years. Paul Goldberg became publisher in January 2011 and has continued to expand coverage of the oncology profession, drug development, and government funding and oversight of cancer research.
Follow us on Twitter: @TheCancerLetter
 Paul Goldberg (Publisher) joined The Cancer Letter in 1986. He broke the story that
led to the ImClone scandal and the key stories in the controversy over
erythropoiesis-stimulating agents. His reporting on the pharmaceutical
and biotechnology industry has triggered numerous investigations by
Congressional committees and law enforcement agencies and has been
recognized by the Washington DC Professional Chapter of the Society of
Professional Journalists, the Gerald Loeb Awards, and the Newsletter
and Electronic Publishers Foundation. He was a reporter for the Wichita
(KA) Eagle and the Reston Connection. He authored a history of the
Helsinki Watch group in the former USSR, called "The Final Act"
(William Morrow, 1988), and co-authored, with Ludmilla Alexeyeva, "The
Thaw Generation: Coming of Age in the Post-Stalin Era" (Little, Brown,
1990; and in paperback, University of Pittsburgh Press). Goldberg also
translated from the Russian, "To Live Like Everyone," the memoirs of
the late dissident Anatoly Marchenko (Henry Holt, 1989). He is a
graduate of Duke University with a B.A. in economics (1981).Editorial Policies
- The mission of The Cancer Letter is to report on current and controversial topics in oncology.
- Company
policy doesn't allow the publisher or staff to hold individual stock positions in
healthcare, pharmaceutical, or biotechnology companies.
|
